Skip to main content
PMC home page
Cambridge Open Access logoLink to Cambridge Open Access
. 2019 Oct 28;51(2):212–218. doi: 10.1017/S003329171900299X

The reality of at risk mental state services: a response to recent criticisms

Alison R Yung 1,2,3,✉, Stephen J Wood 2,3,4, Ashok Malla 5, Barnaby Nelson 2,3, Patrick McGorry 2,3, Jai Shah 5
PMCID: PMC7893503  PMID: 31657288

Abstract

Background

In the 1990s criteria were developed to detect individuals at high and imminent risk of developing a psychotic disorder. These are known as the at risk mental state, ultra high risk or clinical high risk criteria. Individuals meeting these criteria are symptomatic and help-seeking. Services for such individuals are now found worldwide. Recently Psychological Medicine published two articles that criticise these services and suggest that they should be dismantled or restructured. One paper also provides recommendations on how ARMS services should be operate.

Methods

In this paper we draw on the existing literature in the field and present the perspective of some ARMS clinicians and researchers.

Results

Many of the critics' arguments are refuted. Most of the recommendations included in the Moritz et al. paper are already occurring.

Conclusions

ARMS services provide management of current problems, treatment to reduce risk of onset of psychotic disorder and monitoring of mental state, including attenuated psychotic symptoms. These symptoms are associated with a range of poor outcomes. It is important to assess them and track their trajectory over time. A new approach to detection of ARMS individuals can be considered that harnesses broad youth mental health services, such as headspace in Australia, Jigsaw in Ireland and ACCESS Open Minds in Canada. Attention should also be paid to the physical health of ARMS individuals. Far from needing to be dismantled we feel that the ARMS approach has much to offer to improve the health of young people.

Key words: At risk mental state, clinical high risk, prodromal, psychosis, schizophrenia, ultra high risk

In the 1990s criteria were developed to detect individuals at high risk of developing a psychotic disorder, the at risk mental state (ARMS), ultra high risk (UHR) or clinical high risk criteria (Yung et al., 1996). The idea behind their development was that detection and intervention in these individuals may result in delay or even prevention of psychotic disorder, and reduction in distress associated with the early phases of illness. ARMS individuals are symptomatic and help-seeking, and specific services have been developed for this group. Such services are available in several continents, and management of ARMS individuals is now included in clinical guidelines across Australia (Orygen Research Centre, 2010), England (National Institute of Clinical Excellence, 2014), Canada (Addington et al., 2017) and Europe (Schultze-Lutter et al., 2015).

Recently Psychological Medicine published two articles that criticise services for ARMS individuals and suggest that either they be restructured and renamed (Moritz et al., 2019) or that they should be replaced by a ‘public health approach’ (Ajnakina et al., 2019). In this paper we present the perspective of some ARMS clinicians and researchers. We deal with the specific criticisms and conclude with our recommendations for the future of ARMS services.

Moritz et al. (2019) provide four criticisms:

  • (1)

    These services are stigmatising and cause fear of psychosis.

  • (2)

    Longer duration of untreated psychosis (DUP) is only weakly correlated with poor outcome.

  • (3)

    The criteria have poor predictive validity for psychosis.

  • (4)

    There is little evidence that interventions prevent transition to psychosis. Instead services should provide needs-based care.

In addition to argument 3 above, Ajnakina et al. (2019) also state that:

  • (5)

    Individuals accessing these services are not representative of all the people at risk of psychotic disorder.

  • (6)

    Sub-threshold psychotic symptoms, the hallmark of the ARMS criteria, are found in disorders such as anxiety and depression. Therefore the presence of these sub-threshold psychotic symptoms should not indicate that a person is at risk of psychotic disorder.

  • (7)

    People meeting ARMS criteria have already started the process of developing psychotic disorder and therefore intervention at this stage is too late.

  • (8)

    A public health approach to prevent psychosis would be more effective than ARMS services.

ARMS services are stigmatising and cause fear of psychosis

Moritz et al. present little evidence to support this contention. They cite Corcoran et al. (2005), who explored the issue of the stigma that may occur by being identified as ‘at risk’. Corcoran et al., did not include any empirical data examining the effect of seeking help at an ARMS service or being labelled as ‘at risk’, but instead explored the issue from a hypothetical perspective. They discussed how being perceived as ‘at risk’ could vary, depending on the level of symptoms, the family's reactions and reactions of others, such as teachers. While they acknowledge that being perceived ‘at risk’ may lead to an individual feeling ‘a little bit sick’, it may also be beneficial by offering hope of treatment.

Moritz et al. also cite Yang et al. (2013) in support of their belief that ARMS services are stigmatising. However, Yang et al. did not directly examine this issue either. Their study was of college students who were asked about stigmatising attitudes to people labelled as having ‘psychosis risk’. If information was provided about the meaning of ‘psychosis risk’ the attitudes of participants towards individuals with this ‘diagnosis’ were no more stigmatising than their attitudes towards people with anxiety or depression.

The one study with data from ARMS individuals that Moritz et al. include to support their claim is Rüsch et al. (2015). However this study sample is mixed and includes participants deemed to be at risk of bipolar disorder and participants considered at risk of psychosis due to the presence of basic symptoms as assessed by the Schizophrenia Proneness Interview (Schultze-Lutter et al., 2004). Less than half met ARMS criteria, and it is not clear what was communicated to them about risk or what label was used.

It would have been useful for Moritz et al. to discuss the several papers that counter their assertion. For example, ARMS individuals have reported valuing the opportunity to speak about their unusual experiences (Byrne and Morrison, 2010; Welsh and Tiffin, 2012), and indeed found it important for recovery. The symptoms themselves were noted as causing a ‘fear of going mad’ (Byrne and Morrison, 2010, 2014), and disclosing them to a clinician was seen as beneficial, with reduced distress and anxiety, feeling they were going to get help, increased understanding of the symptoms and improved coping (Byrne and Morrison, 2014). Even being asked questions from a structured interview alone was found to be reassuring (Byrne and Morrison, 2014), perhaps because this helped individuals to understand that others had similar experiences. They also valued being informed about their condition (Welsh and Tiffin, 2012; Kim et al., 2017). Being given such information has been associated with relief, feeling validated about their experiences and encouraging hope that treatment was available (Welsh and Tiffin, 2012; Yang et al., 2015). In fact, stigma occurs earlier, in association with the distressing symptoms themselves (Yang et al., 2015), fear of being mentally ill, and self-labelling as mentally ill rather than the risk-label. Such fears and self-labelling are already present prior to seeking help and before being designated ‘at risk’ (Corcoran, 2016) and can be targeted as part of treatment for an ARMS.

In fact, the issue of potential stigma has long been recognised in ARMS work (Yung et al., 2010a), and was an argument for not reifying a diagnosis of ‘Psychosis Risk Syndrome’ in the DSM system (Yung et al., 2010a, 2010b). Stigma can be reduced with sensitive and careful communication that takes into account a person's context, including culture, age and cognitive capacity (Kim et al., 2017). Rather than telling individuals that they have a ‘diagnosis’ of ‘Attenuated Psychosis Syndrome’, the recommended approach is one of discussing current symptoms and risk, what being ‘at risk’ of psychosis means, and treatment options to reduce symptoms, distress and risk. Such discussions enable an individual to make informed decisions about treatment. It is important that the dialogue is iterative, not just a one-off communication, and that appropriate support and resources are made available for individuals and their families (Mittal et al., 2015). Thus, far from what Moritz et al. seem to think occurs across ARMS services (‘Perhaps most importantly, the treatment is not hope-oriented. Patients are more or less told that schizophrenia is looming over them, which may stigmatize individuals who will never, in fact, develop psychosis’), clinicians convey that ‘risk’ is not ‘disorder’, that symptoms can improve, and that recovery is possible (Corcoran, 2016). As previously noted, such communication can result in validation and relief.

To further reduce potential stigma, services for ARMS individuals should avoid being located in mental health institutions that provide services for people with established psychotic disorders. The first ARMS service, the Personal Assessment and Crisis Evaluation (PACE) Clinic, was established in a generic adolescent health service and later moved into a shopping mall (Yung et al., 1995). Some ARMS services are also embedded in low-stigma enhanced primary care services for young people (the headspace model) (McGorry et al., 2014). Services should have non-stigmatising names, such as ‘PACE’ (Yung et al., 1995), Outreach And Support in South London ‘OASIS’ (Broome et al., 2005), Early Detection Intervention Treatment ‘EDIT’ (Morrison et al., 2012), (Portland Identification and Early Referral) ‘PIER’ (McFarlane and Cook, 2006) and (Clinic for Assessment of Youth at Risk in Montréal) CAYR (Pruessner et al., 2017).

Longer duration of untreated psychosis is only weakly correlated with poor outcome

Moritz et al. present a poorly articulated argument as to why a significant but relatively weak correlation between long DUP and poor outcome in schizophrenia patients is relevant to their criticism of ARMS services. Despite this implied linkage, they make no overt connection between the two. We speculate that they could be referring to one of the benefits of individuals engaging in ARMS services: that if a psychotic disorder occurs while being managed by such a service, then DUP should be minimal. This results in reduced time experiencing full-threshold psychotic symptoms, and hence less suffering. Such minimal DUP has been shown to be associated with improved outcomes, with a non-linear relationship. For example, a systematic review and individual patient data meta-analysis showed that individuals with a DUP less than 9 months had a substantially greater negative symptom reduction than those with a DUP of greater than 9 months (Boonstra et al., 2012). DUP of less than 6 months was found to be associated with better outcomes in studies from the UK (Birchwood et al., 2013), Poland (Cechnicki et al., 2014), rural China (Ran et al., 2018) and Canada (Dama et al., 2019) and less than 31 days in a study from Hong Kong (Tang et al., 2014). These findings suggest that very short DUP may have a marked effect on symptom reduction, highlighting this role of ARMS services for those who develop psychotic disorder.

The criteria have poor predictive validity for psychosis

Both Moritz et al. and Ajnakina et al. make this point. We have always acknowledged that the proportion of ARMS individuals developing psychotic disorder is less than 50%. Indeed some of us were the first to report a declining transition rate (Yung et al., 2007) and have continued to explore potential reasons for this (Hartmann et al., 2016). Despite this, the ARMS criteria have fairly good validity and reliability, meaning that the ARMS can be differentiated from psychotic disorder and from mental states below the ARMS threshold, and that there tends to be agreement between clinicians about assignment of an individual into one of these groups (Woods et al., 2009), especially if the evaluators are trained in the use of a specialised instrument (Nelson et al., 2008). Further, the ARMS criteria are relatively specific for psychotic disorders (given their low incidence in the general population) (Woods et al., 2009; Yung and Lin, 2016). And, while a majority of ARMS individuals do not develop psychotic disorder in the short term, it is not clear how many of these ‘false positives’ might be ‘false false positives’ – that is, they would have developed psychosis but for a change in circumstance or an intervention (Yung et al., 1996). They may therefore develop a psychotic disorder later.

It is also important to point out that a finding of 22% of ARMS individuals developing psychotic disorder within one year (Fusar-Poli et al., 2012) is higher than the annual rate of development of dementia from mild cognitive impairment of 9.6% (Mitchell and Shiri-Feshki, 2009) and development of diabetes from pre-diabetes of 5–10% (Tabák et al., 2012). Further, people with pre-diabetes are asymptomatic, while, ARMS individuals are help-seeking, distressed and symptomatic. Indeed, ARMS individuals have been found to have higher levels of stress and lower protective factors than individuals with first episode psychosis, underlining the fact that treatment is justified (Pruessner et al., 2011).

Moritz et al. note that ARMS individuals have other poor outcomes apart from the development of psychotic disorder. Our group has previously reported this, and discussed the need to assess and target other poor outcomes, such as poor social functioning, non-psychotic disorders such as anxiety and depression, persistent attenuated psychotic symptoms and persistent negative symptoms (Yung et al., 2010a, 2010b; Lin et al., 2015; Yung et al., 2019). But just because other poor outcomes can occur in ARMS individuals, this does not mean that the development of psychotic disorder is any less important. In fact, the evidence that the presence of attenuated psychotic symptoms is associated with a range of poor outcomes underlines the value in assessing and treating both these symptoms and other sources of distress, regardless of whether the outcome is psychotic disorder.

Moritz et al. confuse their argument about predictive validity by discussing the use of self-report instruments to detect those at risk of psychotic disorder. They rightly point out that such questionnaires include terms that can be misinterpreted. They then state that, ‘We regard it as a great step forward that assessments in this area are increasingly incorporating interviews’. We encourage Moritz et al. to read the relevant literature in the field, which shows that structured interviews such as the Comprehensive Assessment of At Risk Mental States (Yung et al., 2005) and the Structured Interview for Prodromal Syndromes (Miller et al., 2002) have always been central to identifying ARMS individuals, and are the most widely accepted instruments for the identification of the ARMS.

There is little evidence that interventions prevent transition to psychosis. Instead services should provide needs-based care

Moritz et al. draw this conclusion based on two recent network meta-analyses by Davies et al. (Davies et al. 2018a, 2018b). These studies compared interventions in the ARMS group against each other and to a ‘needs based intervention’ group. Davies et al. conclude that no specific pharmacological or psychological treatment was superior to needs-based intervention for reducing transition risk over 6 and 12 months (Davies et al., 2018a) or reducing attenuated psychotic symptoms (Davies et al., 2018b). These network meta-analyses have recently been criticised on methodological grounds (Nelson et al., 2018a). For example, their ‘needs-based intervention’ group combined data from multiple studies, despite the likelihood that the nature of such interventions would differ markedly across studies, due to different service systems, background treatments and the quality of the relationship between patients and the clinicians assessing need and delivering care. Additionally, most of these ‘needs-based interventions’ included active treatment components, such as supportive therapy, problem solving (Nelson et al., 2018b) and supportive monitoring (Byrne and Morrison, 2014). These are all effective in reducing distress, symptoms and risk for psychotic disorder and are provided in ARMS services. The misclassification of an active control group that included cognitive therapy in a large trial further compounded Davies et al.'s error (Nelson et al., 2018a). The conclusion that no treatment is effective is at odds with several meta-analyses that showed a risk reduction through use of specific treatment in ARMS patients (Stafford et al., 2013; van der Gaag et al., 2013; Hutton and Taylor, 2014; Schultze-Lutter et al., 2015). And while outcomes are variable in ARMS patients, symptoms and functioning tend to improve even with non-specific treatment (Nelson et al., 2018b). More research is needed into those ARMS patients who remain symptomatic and functionally impaired, perhaps with a focus on negative symptoms in this group (Yung et al., 2019).

Moritz et al. state that, rather than focusing on reducing risk for transition to psychotic disorder, ARMS services should provide needs-based care. Ajnakina et al. similarly fall into this falsely dichotomous position of thinking that services either target psychosis risk reduction or provide treatment based on need. In fact, ARMS services have always had such a dual purpose (Yung et al., 1995, 1996): amelioration, delay or prevention of psychosis onset AND management of current symptoms and psychological and functional difficulties. The problem with only focusing on needs-based treatment is that this ignores the fact the ARMS individuals may have different underlying risks for various trajectories. We need to improve our ability to differentiate these. In the meantime, we need to recognise that someone who presents with attenuated psychotic symptoms and depression likely has different underlying processes than someone with depression and no attenuated psychotic symptoms, as evidenced by the worse outcome in the former group compared to the latter (Wigman et al., 2012; Heinze et al., 2018). As noted above, the presence of attenuated psychotic symptoms is associated with a range of poor outcomes.

Individuals accessing these services are not representative of all the people at risk of psychotic disorder

This issue raised by Ajnakina et al. is fundamentally a problem of the relatively poor reach of ARMS services. Ajnakina et al. draw this conclusion from studies from a single ARMS clinic in South London (Ajnakina et al., 2017). They state that individuals who attended their ARMS service and later developed psychosis were more likely to be born in the UK than those who developed psychosis without accessing their ARMS service. However, if the population of their ARMS service overall is considered, then the finding was that black and other minority ethnic background individuals were significantly over-represented in the ARMS group compared to the local population, with the majority being born outside the UK (Byrne et al., 2019). There was an even higher proportion of black service users in the first episode service compared to the background population. This study also found that black patients at the ARMS service were no more likely to make a transition to psychotic disorder than those with white British ethnicity, despite the greater than 6-fold higher incidence of psychosis among black people from the same geographical area (Fearon et al., 2006). Together these findings suggest that (i) their ARMS service was successful at engaging people from ethnic minorities; (ii) nonetheless, a substantial number of individuals from ethnic minority backgrounds did not access the ARMS service before developing psychosis and (iii) providing mental health care to people from ethnic minorities with an ARMS may help to reduce the risk of subsequent psychotic disorder in these vulnerable groups (Byrne et al., 2019).

Finally, another reason for the low number of people accessing early psychosis services via an ARMS service might be that some ARMS patients are prevented from developing psychotic disorder, as suggested by Byrne et al. in relation to minority ethnic group patients in the South London ARMS clinic. Rather than calling for the dismantling of their service, Ajnakina et al. could be advocating for more resources to increase the accessibility and acceptability of their service more widely.

Attenuated psychotic symptoms are found in disorders such as anxiety and depression. Therefore presence of such symptoms should not indicate that a person is at risk of psychotic disorder

Individuals with anxiety and depression and attenuated psychotic symptoms (above a predefined level) will meet ARMS criteria. Such individuals may develop a psychotic disorder, persistent or recurrent mood or anxiety disorder, impaired psychosocial functioning, persistent attenuated psychotic experiences or a combination of these. They may also not develop any disorder and symptoms and functioning might resolve over time (Lin et al., 2015). Currently it is not possible to tell which trajectory an individual will take based on baseline clinical characteristics. We have previously argued that attenuated psychotic symptoms are not all the same, and may be indicators of three different underlying processes: (a) an expression of an underlying fundamental disturbance suggesting vulnerability to a psychotic disorder such as schizophrenia; (b) clinical ‘noise’ around an ultimately non-psychotic syndrome and (c) transient, benign or self-limiting experiences that are not associated with distress, disability or risk of disorder (Yung et al., 2010b). Research distinguishing these subtypes and examining factors that increase or decrease risk of psychotic disorder ARMS individuals is ongoing in several multi-site studies.

Ajnakina et al. state that, ‘The presence of psychotic symptoms in themselves should not be seen as an indication of the risk to making the transition’ (our emphasis). This position is contrary to decades of research that ARMS criteria do predict onset of psychotic disorder and research that shows that anxiety and depression are frequently present in the prodromal phase before a first psychotic episode (Yung and McGorry, 1996). Such sentiment may result in delayed access to appropriate care for ARMS individuals, as the significance of their attenuated psychotic symptoms may not recognised.

People meeting ARMS criteria have already started the process of developing psychotic disorder and therefore intervention at this stage is too late

This pessimistic stance of Ajnakina et al. also reflected in the statement of Moritz et al. that, ‘we still have no treatment that can justify hope in so-called prodromal individuals’ (page 4), is at odds with numerous intervention trials and meta-analyses, and the data from the South London service in relation to ethnic minorities (see above). These statements indicate that both critic groups believe that the ARMS criteria are indicative of impending psychotic disorder. This belief is also reflected in both group's use of the term ‘prodromal’, which suggests inevitable progression to psychotic disorder (Yung et al., 1996). Their pessimism also contradicts their earlier points – that most individuals meeting ARMS criteria will not go on to develop a psychotic disorder – and is inconsistent with the idea that ARMS individuals should receive needs-based care to relieve current problems and distress. Even if one thought that psychotic disorder is already developing, such treatment is justified to reduce suffering, and reduce DUP.

A public health approach to prevent psychosis would be more effective than ARMS services

Ajnakina et al. display binary thinking in believing that the existence of ARMS services equates to the non-existence of a public health approach and that a ‘public health approach’ applies only to the general population. However ‘public health’ is much broader than this and refers to ‘prolonging life and promoting health’ (Winslow, 1920) (p. 20). Most individuals with a first episode of psychosis pass through an ARMS phase but only a minority gain access to an ARMS service (Shah et al., 2017). Enabling these individuals to access care at a service that could reduce their symptoms, distress and risk of developing psychotic disorder is a public health approach. More needs to be done to improve access to ARMS services.

The recommendations of Moritz et al.

In contrast to Ajnakina et al. who believe that the time for ARMS clinics has ‘gone’, Moritz et al. believe that they should be renamed, that they should provide only needs-based care, that antipsychotics should not be prescribed, that a categorical view of mental illness be avoided and a staged approach be used. They call for a ‘hope-oriented’ service, which is ironic given they believe that no treatment can justify hope. In response to their recommendations:

Services should be renamed

We agree that calling such services ‘Prodromal Clinics’ and using the term ‘prodromal’ should be avoided, for reasons described above. However a recent study found that the terms ARMS, UHR or ‘Attenuated Psychotic Symptoms’ were not thought to be stigmatising by ARMS individuals and only a minority thought these names should be changed (Kim et al., 2017). Clinicians viewed these terms as more stigmatising than ARMS individuals themselves. This finding is consistent with Moritz et al.'s (professional) opinion that ARMS services are stigmatising despite empirical evidence to the contrary when ARMS individuals themselves are asked (see above).

Antipsychotics should not be used

Antipsychotics are not the usual treatment for ARMS individuals. Australian, Canadian and European guidelines recommend that they only be used in exceptional circumstances, such as if symptoms are severe and progressive and have not responded to psychological therapy (Orygen Research Centre, 2010; Schultze-Lutter et al., 2015; Addington et al., 2017). English guidelines do not recommend them at all (National Institute of Clinical Excellence, 2014). Despite this, their use is variable across services. Services in the US seem to prescribe antipsychotics more readily than those in Australia, the UK, Canada and Switzerland (Yung, 2010), and we agree that this is not justified in most cases.

A categorical view of mental illness should be avoided and a staged approach used

We appreciate Moritz et al. endorsing the clinical staging model in psychiatry, which we first described over a decade ago (McGorry et al., 2006). The model attempts to determine the position of an individual along a continuum of illness, with interventions tailored accordingly. ARMS patients are considered to be at Stage 1b – recognising that they are symptomatic and in need of intervention, but that a clear cut severe diagnosable mental disorder is not present.

Criticism of Moritz et al. and Ajnakina et al.

Both Moritz et al. and Ajnakina et al. conflate first episode psychosis with schizophrenia. Moritz et al. claim that clinicians working in ARMS services put ‘a strong emphasis on the (relatively low) possibility of schizophrenia’ (p. 3) and that patients are told that ‘schizophrenia is looming over them’ (p. 1). Ajnakina et al. state that the ARMS criteria are ‘schizophrenia-light’. First episode psychosis is not the same as schizophrenia and not all individuals with a first episode of psychosis will develop the functional difficulties associated with this clinical syndrome, especially if early detection and comprehensive care is provided (Correll et al., 2018). Moritz et al., incorrectly cite papers about Early Intervention for Psychosis services (Birchwood and Macmillan, 1993; McGorry et al., 1996) when they refer to ARMS services, which they also incorrectly call ‘prodromal clinics’. Their section on stigma includes irrelevant and misleading citations. For example, they cite their own paper that found that fear of becoming psychotic was prevalent in individuals with obsessive compulsive disorder and depression (Miegel et al., 2019). This paper actually supports our above argument that fear of becoming psychotic is associated with the symptoms themselves rather than management in an ARMS service. They cite papers by Corcoran (Corcoran et al., 2005) and Yang (Yang et al., 2010) that do not contain any data from ARMS individuals and fail to cite the more recent papers from these authors (Corcoran, 2016) (Yang et al., 2015), both of which refute their position.

Recommendations for the future of ARMS services

First, the assessment of attenuated psychotic symptoms is important. These symptoms are often distressing, can lead to maladaptive behaviours and their presence indicates risk for psychotic disorder and other poor outcomes. Cognitive behaviour therapy approaches have been developed specifically for such symptoms and have been found to be effective and non-stigmatising (Morrison et al., 2004, 2013). Second, while we acknowledge that being labelled as at risk of schizophrenia may be stigmatising, it is the symptoms themselves that seem to be more of a concern for individuals. Access to care at an ARMS service can play a role in reducing fear and stigma and providing hope for recovery. We have included recommendations for how stigma related to attending an ARMS service might be minimised. Third, a new approach to detection of ARMS individuals can be considered. This approach can harness broad youth mental health services, such as headspace in Australia Jigsaw in Ireland and ACCESS Open Minds in Canada (Illback and Bates, 2011; McGorry et al., 2014; Malla et al., 2019), where young people can seek help and could be screened for attenuated psychotic symptoms as part of a clinical assessment. This approach could lead to a greater proportion of ARMS individuals receiving specialised care for their attenuated psychotic symptoms and other needs. Fourth, attention should be paid to the physical health of ARMS individuals, who often display cardiometabolic risk factors (Carney et al., 2016). Finally, more research is needed into ARMS individuals who develop psychotic disorder despite receiving treatment at ARMS services. Understanding the pathophysiology and psychosocial factors of these individuals could lead to targeted hypothesis-driven interventions. Far from needing to be dismantled we feel that the ARMS approach has much to offer to improve the health of young people.

Financial support

ARY is funded by the National Health and Medical Research Council (NHMRC) (Principal Research Fellowship 1136829) and by a Senior Investigator award from the National Institute of Health Research, SJW is funded by the Medical Research Council (MR/K013599/1), AM is funded partially from the Canada Research Chairs Program, BN is funded by the NHMRC (Senior Research Fellowship 1137687), PM is funded by the NHMRC (Senior Principal Research Fellowship 1155508) and JS is supported by a clinician-scientist salary award from the Fonds de Recherche du Québec–Santé.

Conflict of interest

None.

References

  1. Addington J, Addington D, Abidi S, Raedler T and Remington G (2017) Canadian treatment guidelines for individuals at clinical high risk of psychosis. Canadian Journal of Psychiatry 62, 656–661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ajnakina O, Morgan C, Gayer-Anderson C, Oduola S, Bourque F, Bramley S, Williamson J, MacCabe JH, Dazzan P, Murray RM and David AS (2017) Only a small proportion of patients with first episode psychosis come via prodromal services: a retrospective survey of a large UK mental health programme. BMC Psychiatry 17, 017–1468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ajnakina O, David AS and Murray RM (2019) ‘At risk mental state’ clinics for psychosis – an idea whose time has come – and gone!. Psychological Medicine 49, 529–534. [DOI] [PubMed] [Google Scholar]
  4. Birchwood M and Macmillan F (1993) Early intervention in schizophrenia. Australian and New Zealand Journal of Psychiatry 27, 374–378. [DOI] [PubMed] [Google Scholar]
  5. Birchwood M, Connor C, Lester H, Patterson P, Freemantle N, Marshall M, Fowler D, Lewis S, Jones P, Amos T, Everard L and Singh SP (2013) Reducing duration of untreated psychosis: care pathways to early intervention in psychosis services. British Journal of Psychiatry 203, 58–64. [DOI] [PubMed] [Google Scholar]
  6. Boonstra N, Klaassen R, Styema S, Marshall M, de Haan L, Wunderink L and Wiersma D (2012) Duration of untreated psychosis and negative symptoms – a systematic review and meta-analysis of individual patient data. Schizophrenia Research 142, 12–19. [DOI] [PubMed] [Google Scholar]
  7. Broome MR, Woolley JB, Johns LC, Valmaggia LR, Tabraham P, Gafoor R, Bramon E and McGuire PK (2005) Outreach and support in south London (OASIS): implementation of a clinical service for prodromal psychosis and the at risk mental state. European Psychiatry 20, 372–378. [DOI] [PubMed] [Google Scholar]
  8. Byrne R and Morrison A (2010) Young people at risk of psychosis: a user-led exploration of interpersonal relationships and communication of psychological difficulties. Early Intervention in Psychiatry 4, 162–168. [DOI] [PubMed] [Google Scholar]
  9. Byrne R and Morrison A (2014) Young people at risk of psychosis: their subjective experiences of monitoring and cognitive behaviour therapy in the early detection and intervention evaluation 2 trial. Psychology and Psychotherapy: Theory, Research and Practice 87, 357–371. [DOI] [PubMed] [Google Scholar]
  10. Byrne M, Codjoe L, Morgan C, Stahl D, Day F, Fearon P, Fusar-Poli P, Power P, McGuire P and Valmaggia L (2019) The relationship between ethnicity and service access, treatment uptake and the incidence of psychosis among people at ultra high risk for psychosis. Psychiatry Research 272, 618–627. [DOI] [PubMed] [Google Scholar]
  11. Carney R, Cotter J, Bradshaw T, Firth J and Yung AR (2016) Cardiometabolic risk factors in young people at ultra-high risk for psychosis: a systematic review and meta-analysis. Schizophrenia Research 170, 290–300. [DOI] [PubMed] [Google Scholar]
  12. Cechnicki A, Cichocki L, Kalisz A, Błądziński P, Adamczyk P and Franczyk-Glita J (2014) Duration of untreated psychosis (DUP) and the course of schizophrenia in a 20-year follow-up study. Psychiatry Research 219, 420–425. [DOI] [PubMed] [Google Scholar]
  13. Corcoran C (2016) Ethical and epidemiological dimensions of labeling psychosis risk. AMA Journal of Ethics 18, 633–642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Corcoran C, Malaspina D and Hercher L (2005) Prodromal interventions for schizophrenia vulnerability: the risks of being ‘at risk’. Schizophrenia Research 73, 173–184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Correll CU, Galling B, Pawar A, Krivko A, Bonetto C, Ruggeri M, Craig T, Nordentoft M, Srihari V, Guloksuz S, Hui C, Chen E, Valencia M, Juarez F, Robinson D, Schooler N, Brunette M, Mueser K, Rosenheck R, Marcy P, Addington J, Estroff S, Robinson J, Penn D, Severe J and Kane JM (2018) Comparison of early intervention services vs treatment as usual for early-phase psychosis a systematic review, meta-analysis, and meta-regression. JAMA Psychiatry 75, 555–565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Dama M, Shah J, Norman R, Iyer S, Joober R, Schmitz N, Abdel-Baki A and Malla A (2019) Short duration of untreated psychosis enhances negative symptom remission in extended early intervention service for psychosis. Acta Psychiatrica Scandinavica 140, 65–76. [DOI] [PubMed] [Google Scholar]
  17. Davies C, Cipriani A, Ioannidis J, Radua J, Stahl D, Provenzani U, McGuire P and Fusar-Poli P (2018a) Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis. World Psychiatry 17, 196–209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Davies C, Radua J, Cipriani A, Stahl D, Provenzani U, McGuire P and Fusar-Poli P (2018b) Efficacy and acceptability of interventions for attenuated positive psychotic symptoms in individuals at clinical high risk of psychosis: a network meta-analysis. Frontiers in Psychiatry 9, 187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Fearon P, Kirkbride J, Morgan C and Dazzan P (2006) Incidence of schizophrenia and other psychoses in ethnic minority groups: results from the MRC AESOP Study. Psychological Medicine 36, 1541–1550. [DOI] [PubMed] [Google Scholar]
  20. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton M and Barale F (2012) Predicting psychosis: a meta-analysis of evidence. Archives of General Psychiatry 69, 220–229. [DOI] [PubMed] [Google Scholar]
  21. Hartmann JA, Yuen HP, McGorry PD, Yung AR, Lin A, Wood SJ, Lavoie S and Nelson B (2016) Declining transition rates to psychotic disorder in “ultra-high risk” clients: investigation of a dilution effect. Schizophrenia Research 170, 130–136. [DOI] [PubMed] [Google Scholar]
  22. Heinze K, Lin A, Nelson B, Reniers RLEP, Upthegrove R, Clarke L, Roche A, Lowrie A and Wood SJ (2018) The impact of psychotic experiences in the early stages of mental health problems in young people. BMC Psychiatry 18, 214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Hutton P and Taylor PJ (2014) Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis. Psychological Medicine 44, 449–468. [DOI] [PubMed] [Google Scholar]
  24. Illback RJ and Bates T (2011) Transforming youth mental health services and supports in Ireland. Early Intervention in Psychiatry 5, 22–27. [DOI] [PubMed] [Google Scholar]
  25. Kim S-W, Polari A, Melville F, Moller B, Kim J-M, Amminger P, Herrman H, McGorry P and Nelson B (2017) Are current labeling terms suitable for people who are at risk of psychosis? Schizophrenia Research 188, 172–177. [DOI] [PubMed] [Google Scholar]
  26. Lin A, Wood SJ, Nelson B, Beavan A, McGorry P and Yung AR (2015) Outcomes of non-transitioned cases in a sample at ultra-high risk for psychosis. American Journal of Psychiatry 172, 249–258. [DOI] [PubMed] [Google Scholar]
  27. Malla A, Iyer SA-O, Shah J, Joober R, Boksa P, Lal S, Fuhrer R, Andersson N, Abdel-Baki AA-O, Hutt-MacLeod D, Beaton A, Reaume-Zimmer P, Chisholm-Nelson J, Rousseau C, Chandrasena R, Bourque J, Aubin D, Levasseur MA, Winkelmann I, Etter M, Kelland J, Tait C, Torrie J and Vallianatos H (2019) Canadian response to need for transformation of youth mental health services: ACCESS Open Minds (Esprits ouverts). Early Intervention in Psychiatry 13, 697–706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. McFarlane W and Cook W (2006) Portland identification and early referral (PIER): 1-year outcomes in a catchment-area-wide psychosis prevention program. Schizophrenia Research 70, s84. [Google Scholar]
  29. McGorry PD, Edwards J, Mihalopoulos C, Harrigan SM and Jackson HJ (1996) EPPIC: an evolving system of early detection and optimal management. Schizophrenia Bulletin 22, 305–326. [DOI] [PubMed] [Google Scholar]
  30. McGorry PD, Hickie IB, Yung AR, Pantelis C and Jackson HJ (2006) Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Australian and New Zealand Journal of Psychiatry 40, 616–622. [DOI] [PubMed] [Google Scholar]
  31. McGorry PD, Goldstone SD, Parker AG, Rickwood DJ and Hickie IB (2014) Cultures for mental health care of young people: an Australian blueprint for reform. The Lancet. Psychiatry 1, 559–568. [DOI] [PubMed] [Google Scholar]
  32. Miegel F, Jelinek L and Moritz S (2019) Dysfunctional beliefs in patients with obsessive-compulsive disorder and depression as assessed with the Beliefs Questionnaire (BQ). Psychiatry Research 272, 265–274. [DOI] [PubMed] [Google Scholar]
  33. Miller TJ, McGlashan TH, Rosen JL, Somjee L, Markovich PJ, Stein K and Woods SW (2002) Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. American Journal of Psychiatry 159, 863–865. [DOI] [PubMed] [Google Scholar]
  34. Mitchell AJ and Shiri-Feshki M (2009) Rate of progression of mild cognitive impairment to dementia – meta-analysis of 41 robust inception cohort studies. Acta Psychiatrica Scandinavica 119, 252–265. [DOI] [PubMed] [Google Scholar]
  35. Mittal VA, Dean DJ, Mittal J and Saks ER (2015) Ethical, legal, and clinical considerations when disclosing a high-risk syndrome for psychosis. Bioethics 29, 543–556. [DOI] [PubMed] [Google Scholar]
  36. Moritz S, Gawęda Ł, Heinz A and Gallinat J (2019) Four reasons why early detection centers for psychosis should be renamed and their treatment targets reconsidered: we should not catastrophize a future we can neither reliably predict nor change. Psychological Medicine, 1–7. 10.1017/S0033291719001740. [DOI] [PubMed] [Google Scholar]
  37. Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, Parker S and Bentall RP (2004) Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. British Journal of Psychiatry 185, 291–297. [DOI] [PubMed] [Google Scholar]
  38. Morrison A, French P, Stewart S, Birchwood M, Fowler D, Gumley A, Jones P, Bentall R, Lewis S, Murray G, Patterson P, Brunet K, Conroy J, Parker S, Reilly T, Byrne R, Davies L and Dunn G (2012) Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. British Medical Journal 344, e2233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Morrison A, Birchwood M, Pyle M, Flach C, Stewart S, Byrne R, Patterson P, Jones P, Fowler D, Gumley A and French P (2013) Impact of cognitive therapy on internalised stigma in people with at-risk mental states. British Journal of Psychiatry 203, 140–145. [DOI] [PubMed] [Google Scholar]
  40. National Institute of Clinical Excellence (2014) NICE guidelines 178: Psychosis and schizophrenia in adults: treatment and management. Available at http://www.nice.org.uk/guidance/CG178.
  41. Nelson B, Simmons MB, Yung AR, Buckby JA, O'Dwyer L, Francey SM, Leicester S, Bapat S and McGorry PD (2008) Identifying the ultra-high risk (‘prodromal’) population: evaluation of training workshops with mental health services. Australian and New Zealand Journal of Psychiatry 42, 236–243. [DOI] [PubMed] [Google Scholar]
  42. Nelson B, Amminger GP and McGorry PD (2018a) Recent meta-analyses in the clinical high risk for psychosis population: clinical interpretation of findings and suggestions for future research. Frontiers in Psychiatry 9, 1–3. doi: 10.3389/fpsyt.2018.00502. doi: eCollection 2018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Nelson B, Amminger GP, Yuen HP, Wallis N, Kerr M, Dixon L, Carter C, Loewy R, Niendam T, Shumway M, Morris S, Blasioli J and McGorry P (2018b) Staged treatment in early psychosis: a sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients. Early Intervention in Psychiatry 12, 292–306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Orygen Research Centre (2010) Australian Clinical Guidelines for Early Psychosis, 2nd Edn. Parkville: Orygen Research Centre. [Google Scholar]
  45. Pruessner M, Iyer S, Faridi K, Joober R and Malla A (2011) Stress and protective factors in individuals at ultra-high risk for psychosis, first episode psychosis and healthy controls. Schizophrenia Research 129, 29–35. [DOI] [PubMed] [Google Scholar]
  46. Pruessner M, Faridi K, Shah J, Rabinovitch M, Iyer S, Abadi S, Pawliuk N, Joober R and Malla A (2017) The Clinic for Assessment of Youth at Risk (CAYR): 10 years of service delivery and research targeting the prevention of psychosis in Montreal, Canada. Early Intervention in Psychiatry 11, 177–184. [DOI] [PubMed] [Google Scholar]
  47. Ran M-S, Xiao Y, Chui C, Hu X, Yu Y, Peng M, Mao W, Liu B, Chen E and Chan C (2018) Duration of untreated psychosis (DUP) and outcome of people with schizophrenia in rural China: 14-year follow-up study. Psychiatry Research 267, 340–345. [DOI] [PubMed] [Google Scholar]
  48. Rüsch N, Heekeren K, Theodoridou A, Müller M, Corrigan PW, Mayer B, Metzler S, Dvorsky D, Walitza S and Rössler W (2015) Stigma as a stressor and transition to schizophrenia after one year among young people at risk of psychosis. Schizophrenia Research 166, 43–48. [DOI] [PubMed] [Google Scholar]
  49. Schultze-Lutter F, Wieneke A, Picker H, Rolff Y, Steinmeyer EM, Ruhrmann S and Klosterkoetter J (2004) The Schizophrenia Prediction Instrument, Adult Version (SPI-A). Schizophrenia Research 70/1S, 76–77. [Google Scholar]
  50. Schultze-Lutter F, Michel C, Schmidt SJ, Schimmelmann B, Maric N, Salokangas R, Riecher-Rossler A, van der Gaag M, Nordentoft M, Raballo A, Meneghell A, Marshall M, Morrison M, Ruhrmann S and Klosterkotter J (2015) EPA guidance on the early detection of clinical high risk states of psychoses. European Psychiatry 30, 405–416. [DOI] [PubMed] [Google Scholar]
  51. Shah JL, Crawford A, Mustafa S, Iyer S, Joober R and Malla A (2017) Is the Clinical High-Risk State a valid concept? Retrospective examination in a first-episode psychosis sample. Psychiatric Services 68, 1046–1052. [DOI] [PubMed] [Google Scholar]
  52. Stafford MR, Jackson H, Mayo-Wilson E, Morrison AP and Kendall T (2013) Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ 346, f185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Tabák A, Herder C, Rathmann W, Brunner E and Kivimäki M (2012) Prediabetes: a high-risk state for diabetes development. Lancet 379, 2279–2290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Tang J, Chang WC, Hui C, Wong GH, Chan S, Lee E, Yeung WS, Wong C and Tang W (2014) Prospective relationship between duration of untreated psychosis and 13-year clinical outcome: a first-episode psychosis study. Schizophrenia Research 153, 1–8. [DOI] [PubMed] [Google Scholar]
  55. van der Gaag M, Smit F, Bechdolf A, French P, Linszen DH, Yung AR, McGorry P and Cuijpers P (2013) Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophrenia Research 149, 56–62. [DOI] [PubMed] [Google Scholar]
  56. Welsh P and Tiffin P (2012) Observations of a small sample of adolescents experiencing an at-risk mental state (ARMS) for psychosis. Schizophrenia Bulletin 38, 215–218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Wigman JTW, van Nierop M, Vollebergh W, Lieb R, Beesdo-Baum K, Wittchen H-U and van Os J (2012) Evidence that psychotic symptoms are prevalent in disorders of anxiety and depression, impacting on illness onset, risk, and severity – implications for diagnosis and ultra-high risk research. Schizophrenia Bulletin 38, 247–257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Winslow CE (1920) The untilled fields of public health. Science 51, 23–33. [DOI] [PubMed] [Google Scholar]
  59. Woods SW, Addington J, Cadenhead KS, Cannon TD, Cornblatt BA, Heinssen R, Perkins DO, Seidman LJ, Tsuang MT, Walker EF and McGlashan TH (2009) Validity of the prodromal risk syndrome for first psychosis: findings from the North American Prodrome Longitudinal Study. Schizophrenia Bulletin 35, 894–908. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Yang LH, Anglin DM, Wonpat-Borja AJ, Opler MG, Greenspoon M and Corcoran CM (2013) Public stigma associated with psychosis risk syndrome in a college population: implications for peer intervention. Psychiatric Services 64, 284–288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Yang LH, Wonpat-Borja AJ, Opler MG and Corcoran CM (2010) Potential stigma associated with inclusion of the psychosis risk syndrome in the DSMV: an empirical question. Schizophrenia Research 120, 42–48. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Yang L, Link B, Ben-David S, Gill K, Girgis R, Brucato G, Wonpat-Borja A and Corcoran C (2015) Stigma related to labels and symptoms in individuals at clinical high-risk for psychosis. Schizophrenia Research 168, 9–15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Yung AR (2010) Antipsychotic treatment of UHR ('prodromal') individuals. Early Intervention in Psychiatry 4, 197–199. [DOI] [PubMed] [Google Scholar]
  64. Yung AR and McGorry PD (1996) The prodromal phase of first episode psychosis: past and current conceptualisations. Schizophrenia Bulletin 22, 353–370. [DOI] [PubMed] [Google Scholar]
  65. Yung AR and Lin A (2016) Psychotic experiences and their significance. World Psychiatry 15, 130–131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Yung AR, McGorry PD, McFarlane CA and Patton G (1995) The PACE clinic: development of a clinical service for young people at high risk of psychosis. Australasian Psychiatry 3, 345–349. [Google Scholar]
  67. Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC and Rakkar A (1996) Monitoring and care of young people at incipient risk of psychosis. Schizophrenia Bulletin 22, 283–303. [DOI] [PubMed] [Google Scholar]
  68. Yung A, Yuen H, McGorry P, Phillips L, Kelly D, Dell'Olio M, Francey S, Cosgrave E, Killackey E, Stanford C, Godfrey K and Buckby J (2005) Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Australian and New Zealand Journal of Psychiatry 39, 964–971. [DOI] [PubMed] [Google Scholar]
  69. Yung AR, Yuen HP, Berger G, Francey S, Hung T, Phillips LJ and McGorry PD (2007) Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophrenia Bulletin 33, 673–681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Yung AR, Nelson B, Thompson A and Wood SJ (2010a) Should a “Risk Syndrome for Psychosis” be included in the DSMV? Schizophrenia Research 120, 7–15. [DOI] [PubMed] [Google Scholar]
  71. Yung AR, Nelson B, Thompson A and Wood SJ (2010b) The psychosis threshold in ultra high risk (prodromal) research: is it valid? Schizophrenia Research 120, 1–6. [DOI] [PubMed] [Google Scholar]
  72. Yung AR, Nelson B, McGorry PD, Wood SJ and Lin A (2019) Persistent negative symptoms in individuals at ultra high risk for psychosis. Schizophrenia Research 206, 355–361. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Psychological Medicine are provided here courtesy of Cambridge University Press

RESOURCES